Combining Serotonin Reuptake Inhibitors and Bupropion in Partial Responders to Antidepressant Monotherapy

J. Alexander Bodkin, Robert A. Lasser, James D. Wines, Jr., David M. Gardner, and Ross J. Baldessarini

Published: April 15, 1997

Article Abstract

Background: Many patients with affective illness show partial or otherwise unsatisfactory responses to standard treatments, encouraging trials of combinations of pharmacologically dissimilar antidepressants.

Method: Records of consecutive outpatients with affective disorders only partially responsive to treatment with a serotonin reuptake inhibitor (SRI) or bupropion, alone, were reviewed for changes in specific symptoms and risks of adverse events when an SRI and bupropion were combined.

Results: Greater symptomatic improvement was found in 19 (70%) of 27 subjects during a mean±SD of 11 ± 14 months of combined daily use of bupropion (243±99 mg) with an SRI (31±16 mg fluoxetine-equivalents) than with either agent alone. Adverse effect risks were similar to those associated with each monotherapy, with a >10% incidence of sexual dysfunction (N=11, 41%), insomnia (N=6, 22%), anergy (N=4, 15%), and tremor (N=3, 11%) during combined therapy; there were no seizures.

Conclusion: With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy.

Volume: 58

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Frontothalamic Circuit Abnormalities in Patients With Bipolar Depression and Suicide Attempts

To identify potential markers for suicide risk, this fMRI study looked at neural activity in bipolar depression...

Read More...